LTR Pharma (ASX:LTP) has completed recruitment for its Phase 2 pharmacokinetic clinical study of SPONTAN, a novel intranasal spray designed to provide rapid-acting treatment for erectile dysfunction.
The study marks a critical step in the company’s regulatory journey, with all 27 participants now successfully enrolled across three distinct cohorts.
The final cohort of eight participants is currently undergoing a 15-day residential dosing period at a clinical research facility, where they are receiving both SPONTAN and a control vardenafil tablet.
A feature of the study is the inclusion of a dedicated 65+ age cohort, comprising approximately half of the total participants.
The demographic is traditionally underserved by oral therapies, which often require lower initiation doses due to increased systemic exposure.